Changes in Beneficial Ownership · 4
Rhythm Pharmaceuticals, Inc.
RYTMNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-08-31
- Issuer
- RHYTHM PHARMACEUTICALS, INC.
- Issuer CIK
- 0001649904
- Trading symbol
- RYTM
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Smith Hunter C
- Reporting owner CIK
- 0001636385
- Relationship
- Officer
- Officer title
- Chief Financial Officer
- Address
- C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON, MA, 02116
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-31 | M · Form 4[F1] | 57,187 | A | 25.79 | 176,798 | D |
| Common Stock | 2026-08-31 | S · Form 4[F1] | 23,072 | D | 104.5871[F2] | 153,726 | D |
| Common Stock | 2026-08-31 | S · Form 4[F1] | 11,514 | D | 105.3702[F3] | 142,212 | D |
| Common Stock | 2026-08-31 | S · Form 4[F1] | 28,188 | D | 106.2029[F4] | 114,024 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy) | 25.79 | 2026-08-31 | M · Form 4[F1] | 57,187 | D | 0 | [F5] | 2028-02-13 | Common Stock | 57,187 | 3,813 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026.↩ 1↩ 2↩ 3↩ 4↩ 5
- F2
- The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.04 to $105.03 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
- F3
- The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.04 to $106.01 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
- F4
- The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.05 to $106.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
- F5
- This option was granted on February 14, 2018 and the shares underlying this option vested in sixteen equal quarterly installments.↩ 1
Signature 1
- Signed
- /s/ Stephen Vander Stoep, attorney-in-fact for Hunder Smith
- Date
- 2026-09-01